Global KRAS Inhibitors Drug Market Clinical Trials Forecast 2028

"Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" Report Highlights:

 

  • KRAS Inhibitors Market Opportunity: > USD 4.5 Billion by 2028
  • Initially US To Dominate KRAS Inhibitors Market: >70% Market Share
  • Number of KRAS Inhibitors In Trials: > 45 Drugs
  • Number of Approved Drugs: 1 (Lumakras)
  • Lumakras Dosage, Sales, Patent & Price Insight
  • Solid Tumors Targeted Drugs Dominating The Clinical Trials
  • Global KRAS Inhibitors Market Trends & Dynamics
  • Global KRAS Inhibitors Market Future Opportunity Outlook

 

Download Report:

 

 https://www.kuickresearch.com/report-global-kras-inhibitors-market-size-sales

 

Cell growth and division plays a crucial role in the development of cancers and it is regulated by several genes that are expressed over the surface of normal cells while the mutated forms of these genes are present over the cancerous cells. Therefore, mutation in the cell regulatory genes is the leading factor responsible for the occurrence of cancer. KRAS (Kirsten rat sarcoma 2 viral oncogene homolog) is one of the major genes responsible for controlling the cell growth and maintaining normal cell signaling and proliferation. Mutation in the KRAS is observed in various types of cancers, which leads to the uncontrolled cell division and hence inhibiting KRAS mutations can be used as ideal approach for the management of cancers.  

 

Lumakras (sotorasib) is a KRASG12C inhibitor used for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non- small cell lung cancer (NSCLC), following at least one prior systemic therapy. It is a once-daily oral prescription medicine used to treat adults living with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer. Lumakras is a product of Amgen, which got FDA approval on 28 May 2021 under the accelerated approval based on overall response rate (ORR) and duration of response (DOR). Since its entry into the market, the drug has shown high adoption rates. For instance in 2021, the sales of the drug reached US$ 90 Million, thus exhibiting high growth rates.

 

The encouraging response of Lumakras has also propelled the research and development activities in this segment. Major players are also contributing to market growth through developments. For instance, Mirati Therapeutics, Inc., a clinical-stage targeted oncology corporation, announced positive topline results from the potentially registration-allowing cohort of Phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with advanced non-small-cell lung cancer (NSCLC) harboring the KRASG12C mutation consistent with previous systemic therapy, in September 2021. The company intends to publish detailed data from the KRYSTAL-1 study's continuing Phase 2 registration-enabling cohort in previously treated patients with KRASG12C-mutated NSCLC at a medical congress in 2022. Other key players in market include Eli Lilly, Codiak Bioscience, Merck, Moderna, Boehringer Ingelheim, Revolution Medicines, and others.

 

Apart from this, several pharmaceutical companies are also investing in developing novel diagnostic test for KRAS inhibitors. For instance in 2022, regulatory bodies in US and Japan has granted regulatory approval for Guardant360 CDx liquid biopsy test as a companion diagnostic for identifying patients with metastatic non-small cell lung cancer (NSCLC) who may benefit from treatment with Lumakras (sotorasib), a KRAS G12C inhibitor developed and manufactured by Amgen.

 

The increasing prevalence of the geriatric population across the world is one of the major concerns of healthcare infrastructures globally. As the age of a person increases, it makes their immune systems more fragile to various kinds of cancers. This increase the demand of novel targeted cancer therapies in the market. The promising response of KRAS inhibitor over other available traditional therapies will boost the growth of market. As per our report findings, the global KRAS inhibitor market is expected to surpass US$ 4 Billion by 2028.  

 

The global KRAS inhibitor report involves in depth analysis of the various parameters related to this segment along with the analysis of current as well as future market opportunity. The report also analyzes the wide range of applications of this class in cancer management along with the clinical trends, market drivers, and possible challenges related to KRAS inhibitor market. Further, multiple parameters are considered to forecast and analyze the global, regional and indication based market size for KRAS inhibitors.

 

Contact:

 

Neeraj Chawla

Kuick Research

Research Head

neeraj@kuickresearch.com

+91-9810410366

 

Back to news